Okay. Sure.
question. So the regulatory, – exercise start terms CPET the let acceptance I of I’ll with me of part in of bit question of about guess, the that’s capacity,
level, we’re on So will agency, as again, future as not exceedingly exercise the approved in of into clarity the high been back-and-forth the with try at and had just but that much the that have get its to have details direction, have drugs to going we general can get clear a we on the on the we capacity.
to approved clear most In studies. clinical drugs get approved that in exercise have event of And outcomes fact time capacity. PAH seemingly on clinical on been or the also it’s drugs
of cover way wants really broader that’s and the capacity kind prong cover stretch will. approach a so populations. I’ve dual both We And to a you want not described. then we’re We exercise prevalent to -- in intend that to have patients patient if incident as either big
and clinical us is think prevalent time need for fixed each We capacity a conducive each duration kinds population range to incident conducive have of to to of more to with we’re in population And treatment. that we of something broadest with possible the is looking level is the exercise So believe is get that patients. enables for we program address broad which better to studies those, study a event served anyway. particular of a
trying again So Phase very program. cover X comprehensive a to we’re
as have but the reiterated of exercise an around capacity day in I’d we degree controversy, that I past other With that the on solid discussion had testing capacity cardiopulmonary what not today and with of then construct previously fairly the in PAH of exercise is cardiopulmonary studies, primary and measure We’ve exercise not remain referenced consistent. action exercise FDA that agencies exercise to. setting, I’m CPET some communications think testing venues. approval about has abundantly approvable stated in endpoints They methodology in respect outcome accepted want today And guidance it us clear in I provided measure, foundation. other And discussion made or on in public even Phase our the to to them X its have capacity. we’ve to today communications you the endpoints endpoint just only specific exactly particularly, make as programs. we methodology, that exercise some specifically terms reiterated and capacity that Now, FDA clear possible drugs in sure for refers
that talk clinical to more gets It's event about discussions. that going you those not time we’re can again So a to just clear do and much drugs very approved. study
study, can get also do capacity can drugs exercise approved. that You
about the the push cover physician operational in the into of then not go the to taking spectrum. And I'm details footprints We’re elements. terms experience, and
level As larger. I be to said event we to studies time will just high the be providing a that detail clinical at tend midyear
comment. XXX scripted around as so my We are in estimating patients, mentioned I
where And detail to sites, in and so what of we to patients, get more we the and take about account. regions in therapy into regions those geographic how provide background expect the number those will we know be will terms the that of important
provide cross dot want need the a that fashion. So and much said, as sure and just timely of we make providing lock detail everything in we we’re information as Amit i’s the can all I’s at more we of we the to that to
start will midyear. that around So
